Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 12, 2022 16:05 ET | Source: MaxCyte, Inc

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
March 22, 2022 16:05 ET | Source: MaxCyte, Inc

MaxCyte Reports Fourth Quarter and Full Year Financial Results

GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to...
March 09, 2022 16:15 ET | Source: MaxCyte, Inc

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
February 24, 2022 08:00 ET | Source: MaxCyte, Inc

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
February 14, 2022 08:00 ET | Source: MaxCyte, Inc

MaxCyte to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
February 11, 2022 17:00 ET | Source: MaxCyte, Inc

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
February 01, 2022 02:00 ET | Source: MaxCyte, Inc

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering,...
January 24, 2022 02:30 ET | Source: MaxCyte, Inc

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.7 millionInstalled base of greater than 500 instruments 15 SPLs, covering...
November 12, 2021 08:00 ET | Source: MaxCyte, Inc

MaxCyte to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
November 10, 2021 16:00 ET | Source: MaxCyte, Inc

MaxCyte Reports Third Quarter Financial Results

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...